ICH E3 section 11.4.7 provides a dedicated place for efficacy conclusions after the detailed efficacy analyses and supporting displays. Do not use the conclusion to overrule the detailed analyses or convert exploratory findings into confirmed primary results.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
The efficacy-conclusions subsection synthesizes what the reported analyses support about treatment efficacy without introducing new results.
Key details
Core IssueICH E3 section 11.4.7 provides a dedicated place for efficacy conclusions after the detailed efficacy analyses and supporting displays.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Do not use the conclusion to overrule the detailed analyses or convert exploratory findings into confirmed primary results.
Further guidance
Content
Base the conclusion on the prespecified and reported efficacy evidence, acknowledging material limitations, inconsistencies, subgroup findings, or missing-data effects where relevant.
Purpose
The efficacy-conclusions subsection synthesizes what the reported analyses support about treatment efficacy without introducing new results.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 Section 13 calls for a concise discussion of efficacy and safety results, the risk-benefit relationship, unexpected findings, clinical relevance, unresolved issues, and implications for future studies without merely repeating results or introducing new ones. This section interprets results already presented; it should not simply duplicate result tables and should not introduce new study results that were not reported elsewhere.
ICH E3 Section 9.5 calls for identification of the efficacy and safety variables assessed, the methods and timing of assessments, and the people or procedures responsible for measurements, often with a schedule or flow chart. This section defines variables and assessment methods; it is not the same artifact as the later efficacy or safety result tables.
ICH E3 section 11.4.2.6 calls for efficacy analyses in relevant patient subsets to be presented or discussed when subgroup evidence is important to interpretation. Keep a defined efficacy subset distinct from the primary analysis population and from exploratory subgroup claims that require their own interpretation.
ICH E3 reserves section 14.2 for efficacy tables, figures, and graphs referred to in the report but not included in the main text, allowing detailed displays to support the core efficacy analysis. This page is about supporting ICH E3 efficacy displays, not the broader Efficacy Results section that explains analyses and interprets findings in the report body.
ICH E3 appendix 16.2.6 designates individual efficacy response data as a patient-level listing in the clinical study report supporting material. This is a patient-level listing function, not a substitute for aggregate efficacy tables, statistical analyses, or the broader individual-patient-data appendix overview.
ICH E3 section 9.5.3 calls for the primary efficacy variable or variables to be specified and for their role in evaluating efficacy to be clear. This page is limited to the planned primary-efficacy-variable subsection; detailed statistical analysis belongs in the statistical-methods and efficacy-results sections.
ICH E3 section 12.6 calls for an overall safety evaluation that highlights important events, identifies patients or groups at increased risk, and discusses implications for possible use of the investigational product. This is an overall safety synthesis under ICH E3 12.6, not a duplicate event listing, safety table, or patient narrative.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
